Skip to content
Brilliant Blue Biosciences logoBrilliant BlueBiosciences
← Research & Industry News
External source

First Patient Dosed in Phase 2b/3 NAAVIGATE Trial of Gene Therapy Surabgene Lomparvovec in Diabetic Retinopathy

REGENXBIO will receive a $100 million milestone from AbbVie following the first dosing in NAAVIGATE, a pivotal trial evaluating one-time suprachoroidal gene therapy in nonproliferative diabetic retinopathy without center-involved macular edema.

Published by
CGTLive
Evidence type
Clinical

REGENXBIO will receive a $100 million milestone from AbbVie following the first dosing in NAAVIGATE, a pivotal trial evaluating one-time suprachoroidal gene therapy in nonproliferative diabetic retinopathy without center-involved macular edema.

This item was selected automatically by our daily literature and news monitor because it matches the topics we follow. Read the full story at CGTLive.

Gene Delivery & Transfection

Let's engineer the next delivery breakthrough together

We co-develop nanocarrier and biosensing programmes with pharma, biotech and academic groups — from target selection through scale-up.

ResearchersRequest a technical consultationTalk formulation, characterisation or assay design with one of our scientists.Industry partnersExplore co-developmentFeasibility studies, co-development programmes and licensing.InvestorsExplore the market opportunitySourced market sizes, pipeline, investment and deal data for genetic medicine delivery.
First Patient Dosed in Phase 2b/3 NAAVIGATE Trial of Gene Therapy Surabgene Lomparvovec in Diabetic Retinopathy | Brilliant Blue Biosciences